drugset / Trial / NCT03923270
Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer
Phase 1
Active not recruiting
25 enrolled
H. Lee Moffitt Cancer Center and Research Institute
AstraZeneca · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a randomized multi-arm trial evaluating the safety and efficacy of thoracic radiation therapy followed by either durvalumab as monotherapy or in combination with tremelimumab or olaparib in participants with Extensive-Stage Disease Small Cell Lung Cancer (ES-SCLC) who have completed a first-line platinum-based chemotherapy regimen and achieved ongoing complete response (CR), partial response (PR) or stable disease (SD).
Timeline
- Start
- 2019-06-06
- Primary completion
- 2023-06-01
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Durvalumab | Monoclonal antibody | 1500 mg | Intravenous |
| Subject | Olaparib | Small molecule | 300 mg | Oral |
| Subject | Tremelimumab | Monoclonal antibody | 75 mg | Intravenous |
| Subject | Tremelimumab | Monoclonal antibody | 300 mg | Intravenous |